Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Oncogenic Mutation Detection of Advanced NSCLC Patients by cSMART Liquid Biopsy and Dynamic Monitor of Tyrosine Kinase Inhibitor(TKI) Efficiency in Inner-Mongolia China

NCT02980536 is registered in ClinicalTrials.gov with Berry Genomics Co., Ltd. as lead sponsor.

NCT NCT02980536
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02980536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Oncogenic Mutation Detection of Advanced NSCLC Patients by cSMART Liquid Biopsy and Dynamic Monitor of Tyrosine Kinase Inhibitor(TKI) Efficiency in Inner-Mongolia China
Lead sponsor
Berry Genomics Co., Ltd.
Phase
Observational
Overall status
Unknown status
Start date
November 30, 2016
Completion date
December 31, 2018
Enrollment
129 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma, nonsmall cell lung cancer